Franklin Resources Inc. Increases Stake in Pfizer Inc. $PFE
Franklin Resources Inc. increased its stake in Pfizer Inc. by 3.7% in Q2, owning 16,961,261 shares worth $411 million. Pfizer's stock opened at $25.02, with a market cap of $142.26 billion. The company reported Q3 earnings of $0.87 per share, beating estimates. Pfizer announced a quarterly dividend of $0.43 per share. Analysts have mixed ratings on Pfizer, with a consensus rating of "Hold" and a price target of $28.28.
Franklin Resources Inc. increased its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 3.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 16,961,261 shares of the biopharmaceutical company's stock after purchasing an additional 609,408 shares during the period. Franklin Resources Inc. owned approximately 0.30% of Pfizer worth $411,141,000 at the end of the most recent quarter.
- HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?
Other hedge funds also recently added to or reduced their stakes in the company. Westbourne Investments Inc. purchased a new position in Pfizer in the 1st quarter worth $2,411,000. Bourne Lent Asset Management Inc. raised its stake in shares of Pfizer by 90.8% in the second quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company's stock worth $927,000 after purchasing an additional 18,200 shares during the last quarter. Strs Ohio purchased a new stake in Pfizer in the first quarter valued at approximately $49,968,000. IFM Investors Pty Ltd increased its holdings in Pfizer by 3.8% in the 2nd quarter. IFM Investors Pty Ltd now owns 1,127,143 shares of the biopharmaceutical company's stock worth $27,322,000 after buying an additional 41,263 shares during the period. Finally, Intrua Financial LLC raised its position in Pfizer by 17.4% during the first quarter. Intrua Financial LLC now owns 78,392 shares of the biopharmaceutical company's stock valued at $1,986,000 after acquiring an additional 11,643 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.
Pfizer Price Performance
Pfizer stock opened at $25.02 on Friday. The company's 50 day simple moving average is $24.84 and its 200-day simple moving average is $24.47. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69. The company has a market capitalization of $142.26 billion, a price-to-earnings ratio of 13.31, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54.
- Why GRAIL Stock Could Be Biotech’s Next Big Breakout
Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.08. The firm had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.
Pfizer Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. The ex-dividend date is Friday, November 7th. Pfizer's dividend payout ratio (DPR) is 100.00%.
Wall Street Analysts Forecast Growth
- Eli Lilly Strikes Deal With Trump: Why Shares Are Up 10% Since
A number of brokerages have recently commented on PFE. Wall Street Zen cut shares of Pfizer from a "buy" rating to a "hold" rating in a research note on Sunday, September 28th. Weiss Ratings restated a "hold (c-)" rating on shares of Pfizer in a research note on Wednesday, October 8th. Morgan Stanley dropped their target price on shares of Pfizer from $33.00 to $32.00 and set an "equal weight" rating for the company in a report on Friday, October 10th. The Goldman Sachs Group reissued a "neutral" rating and issued a $26.00 price target on shares of Pfizer in a research note on Wednesday, November 5th. Finally, Bank of America upped their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a "neutral" rating in a research note on Friday, October 3rd. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $28.28.
View Our Latest Report on PFE
Pfizer Company Profile
(Free Report)Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Further Reading
- Five stocks we like better than Pfizer
- Should You Invest in Penny Stocks?
- MarketBeat Week in Review – 11/17 - 11/21
- How to Start Investing in Real Estate
- A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves
- Health Care Stocks Explained: Why You Might Want to Invest
- 12 Analysts Just Raised CrowdStrike Targets—Here’s What They See Coming
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Pfizer Right Now?
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
